Objective: Collagen type II (Col-II) plays a significant role in skeletal development and cartilage homeostasis and its loss with age is associated with degenerative joint diseases such as osteoarthritis (OA). Previously findings establish that the protein deacetylase SirT1 is required for enhanced expression of Col-IIa1, a major cartilage structural component of Col-II. Here we profile the mechanism by which SirT1 activates promoter-driven Col-IIa1 expression. Methods: Chondrocytes derived from human osteoarthritic knee joints were encapsulated in three-dimensional alginate hydrogel microbeads (3D) and compared to paired monolayer (2D, passage 2) cultures derived from the same donor tissue. 3D-cultured cells displayed augmented expression of Col-IIa1 and were subject to serial chromatin immunoprecipitation (ChIP) and ChIP reChIP analyses to characterize epigenetic variations as compared to 2D cultures. Results: ChIP analyses exhibited enrichment for SirT1 and the histone methyl transferase Set7/9, which formed a complex in 3D cultures wherein Col-IIa1 was augmented in expression. Consistent with enriched Set7/9 levels on the Col-IIa1 promoter, ChIP data revealed enriched levels of trimethylation on histone 3 lysine 4 (3MeH3K4). Acetylated H3K9/14 and H4K16 on Col-IIa1 promoters of 3D-cultured chondrocytes were also elevated indicating that SirT1 is enzymatically repressed by Set7/9 on the transactivated Col-IIa1 promoter. Elevated marks of the Histone acetyl transferases GCN5 and P300 also supported the local enrichment of their acetylated histone marks (i.e. H3K9/ 14,H4K5 and H4K16). Conclusions: The data support that Set7/9 is capable of locally repressing SirT1 enzymatic activity on the promoter of Col-IIa1, resulting in its augmented expression dependent on cell morphology. Osteoarthritis (OA) represents the most common form of arthritis and has a substantive clinical and economic impact. Our recent studies have successfully identified numerous genetic loci associated with OA. Despite this, a substantial proportion of the causality for OA remains unexplained. We hypothesize that epigenetic mechanism is an important factor that accounts for the missing heritability in OA and we tested our hypothesis using an epigenome-wide association approach. Methods and Patients: Human cartilage tissue samples were collected from six total hip joint replacement patients, two of which had primary OA and four controls with hip fracture that exhibited no evidence of OA. DNA was extracted from the cartilage samples using DNeasy Blood and Tissue kit. Genome-wide DNA methylation profiling was performed on these six cartilage DNA samples plus additional 18 blood DNA samples from 18 OA patients. The profiling was done using Illumina HumanMethylation450k Beadchip, which measures up w480,000 different CpG sites per sample, covers 96% of RefSeq genes, and provides comprehensive gene region coverage, targeting multiple sites with promoter, 5' UTR, 1st exon, gene body, and 3' UTR. The methylation level at each CpG site was measured by b values varying from 0 (no methylation) to 1 (100% methylation).
NEW INSIGHTS INTO THE MOLECULAR BASIS OF THE METABOLIC ALTERATIONS IN THE OSTEOARTHRITIS (OA) DISEASE
Osteoarthritis (OA) represents the most common form of arthritis and has a substantive clinical and economic impact. Our recent studies have successfully identified numerous genetic loci associated with OA. Despite this, a substantial proportion of the causality for OA remains unexplained. We hypothesize that epigenetic mechanism is an important factor that accounts for the missing heritability in OA and we tested our hypothesis using an epigenome-wide association approach.
Methods and Patients:
Human cartilage tissue samples were collected from six total hip joint replacement patients, two of which had primary OA and four controls with hip fracture that exhibited no evidence of OA. DNA was extracted from the cartilage samples using DNeasy Blood and Tissue kit. Genome-wide DNA methylation profiling was performed on these six cartilage DNA samples plus additional 18 blood DNA samples from 18 OA patients. The profiling was done using Illumina HumanMethylation450k Beadchip, which measures up w480,000 different CpG sites per sample, covers 96% of RefSeq genes, and provides comprehensive gene region coverage, targeting multiple sites with promoter, 5' UTR, 1st exon, gene body, and 3' UTR. The methylation level at each CpG site was measured by b values varying from 0 (no methylation) to 1 (100% methylation).
Results: A series of QC steps were applied to the initial methylation data on 485,577 CpG sites. After QC, we had data on 383,136 autosomal CpG sites, which were included in the subsequent analysis. We found that the distributions of the global methylation levels for the three groups (cartilage DNA for OA, and controls, and blood DNA for OA patients) are bimodal, which is consistent with previous report. However, blood samples had a significantly higher number of methylated regions than cartilage samples of both OA cases and controls. We found that three CpG sites in the MMP3 gene and one CpG site in MMP13 were demethylated in OA cases compared to controls (all p <0.05), consistent with previous reports. Two CpG sites in MMP9 were associated with OA (all p <0.05), but the effect size was opposite between these two CpG sites. We didn't find any association with ADAMTS4 but found two CpG sites located in the 1st exon of ADAMTS5 were significantly methylated in OA cases (all p<0.01). We found one CpG site in IL-1b was methylated and one CpG site in GDF5 was demethylated in OA. Epigenome-wide association analysis didn't find any signals that reach genome-wide significance level (p<10-7) due to small sample size but found there are many potential OA genes with methylation changes that haven't been reported previously. Conclusion: Our preliminary result demonstrate that global DNA methylation pattern in human cartilage tissue is different from that in blood and we confirmed many of previously reported candidate gene methylation associations with OA. Our study also demonstrated that epigenome-wide approach is feasible to investigate the epigenetic factors in OA.
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